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Mycolic acids are the hallmark of the cell envelope in myco-
bacteria, which include the important human pathogensMyco-
bacterium tuberculosis and Mycobacterium leprae. Mycolic
acids are very long C60–C90 -alkyl -hydroxy fatty acids hav-
ing a variety of functional groups on their hydrocarbon chain
that define several mycolate types. Mycobacteria also produce
an unusually large number of putative epoxide hydrolases, but
the physiological functions of these enzymes are still unclear.
Here, we report that themycobacterial epoxide hydrolase EphD
is involved inmycolic acidmetabolism.We found that orthologs
of EphD fromM. tuberculosis andM. smegmatis are functional
epoxide hydrolases, cleaving a lipophilic substrate, 9,10-cis-ep-
oxystearic acid, in vitro and forming a vicinal diol. The results of
EphDoverproduction inM. smegmatis andM. bovisBCGhma
strains producing epoxymycolic acids indicated that EphD is
involved in the metabolism of these forms of mycolates in both
fast- and slow-growingmycobacteria.Moreover, usingMALDI-
TOF-MS and 1H NMR spectroscopy of mycolic acids and lipids
isolated fromEphD-overproducingM. smegmatis, we identified
new oxygenated mycolic acid species that accumulated during
epoxymycolate depletion. Disruption of the ephD gene in
M. tuberculosis specifically impaired the synthesis of ketomyco-
lates and caused accumulation of their precursor, hydroxymy-
colate, indicating either direct or indirect involvement of EphD
in ketomycolate biosynthesis. Our results clearly indicate that
EphD plays a role in metabolism of oxygenated mycolic acids in
mycobacteria.
The genusMycobacterium comprisesmore than 150 species,
among which pathogens such as Mycobacterium tuberculosis
and Mycobacterium leprae have attracted much attention as
causative agents of tuberculosis and leprosy, respectively. How-
ever, a large number of mycobacterial species can also be found
in various biotopes as saprophytic bacteria (1). Mycobacteria
are characterized by a unique cell wall structure composed of
peptidoglycan linked to a heteropolysaccharide arabinogalac-
tan with its arabinosyl termini esterified bymycolic acids, very-
long-chain fatty acids unique to mycobacteria, and related
genera of the suborder Corynebacterineae (2). Arabinogalac-
tan-bound mycolic acids represent the main lipids of the inner
leaflet of the outer membrane of mycobacteria, also referred to
asmycomembrane. The outer leaflet of thismembrane consists
of a variety of non-covalently associated glycolipids, someof the
most prominent forms of which are trehalose esters of myco-
lates: trehalose monomycolates (TMMs)2 and trehalose dimy-
colates (TDMs) (3).
Mycolic acids are the hallmark of the mycobacterial cell
envelope with a characteristic -alkyl -hydroxy structure and
a very long, C60–C90 hydrocarbon chain. The main meromy-
colate chain is typicallymodified in two distinct positions along
the hydrocarbon chain, with the proximal position closer to the
carboxyl group and the distal position closer to the-end of the
meromycolate (Fig. S1). These modifications include various
functional groups, such as double bonds, methyl groups, cyclo-
propane, and oxygenated groups. The latter are present only at
the distal position of themeromycolate chain and have amethyl
group attached at the adjacent carbon (2). Based on the pres-
ence of functional groups, a few types of mycolic acids were
defined, and interestingly, mycobacterial species synthesize
distinct sets of several mycolic acid classes. For example, in
M. tuberculosis, the least polar -mycolates with two cyclopro-
pane rings can be found, as well asmethoxy- and ketomycolates
(Fig. S1). The fast growing environmental strainM. smegmatis,
which is a widely used model organism in mycobacteriology,
produces mainly -mycolates with two double bonds, shorter
-mycolates and epoxymycolates. The biosynthesis of mycolic
acids involves the production of (i) C22–C26 -alkyl chain by
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the mycobacterial type I fatty acid synthase (FASI) system and
(ii) the meromycolate, which is synthesized by elongation of
C16–C18 FASI products to fatty acids up to C54 long by
enzymes of the type II fatty acid synthase (FASII) system (2).
These precursors then undergo a Claisen-type condensation
forming a -keto product, which is subsequently attached to
trehalose, and its -keto group is reduced (4, 5). The resulting
TMM are further transported across the plasma membrane,
wheremycolates are transferred fromTMMto arabinogalactan
or another TMMmolecule, resulting in the formation of TDM
(6–8).
It is generally accepted that the attachment of functional
groups to the proximal and distal positions of the meromyco-
late is initiated by desaturation of the chain, although neither
the enzyme(s) nor the precise stage at which these reactions
occur have been identified. In M. tuberculosis, the chains with
double bonds serve as the substrates for at least six S-adenosyl
methionine-dependent methyltransferases encoded bymmaA1–
mmaA4, cmaA2, and pcaA genes (9). Although catalytic activ-
ities ofMmaA1,MmaA2, CmaA2, and PcaA give rise to specific
cyclopropane and methyl groups, the methyltransferase
MmaA4 (Hma) has been shown to be required for the produc-
tion of methoxy and ketomycolates (10, 11). Synthesis of oxy-
genated mycolates inM. tuberculosis probably occurs through
a hydroxy fatty acid precursor, which can be either O-methy-
lated by the methyltransferase MmaA3, leading to the produc-
tion ofmethoxymycolates, or further oxidized resulting in keto-
mycolates (12). Studies of protein–protein interactions of core
enzymes of FASII systemwith knownmeromycolatemodifying
enzymes fromM. tuberculosis have strengthened the hypothe-
sis that reactions of modifications of the meromycolate chain
probably take place during its elongation by FASII (13, 14).
The biosynthesis of individual classes of mycolates in
M. smegmatis has been extensively studied, including several
important observations related to the growth of this organism
at different temperatures. In this respect, it was shown that the
amounts of epoxymycolates relative to-mycolates and-my-
colates produced byM. smegmatis, increase at lower tempera-
tures (15). Although most -mycolates inM. smegmatis grown
at 37 °C are diunsaturated, some level of cyclopropanation was
also detected, and it appears to be induced at lower growth
temperatures (16, 17). Temperature-induced changes in
mycolic acid composition were also observed in Mycobacte-
rium thermoresistibile, in which cyclopropanation of -myco-
lates decreased at 55 °C comparedwith 37 °C (18). It is therefore
of significance to address the temperature dependence of
mycolate composition in fast-growing mycobacteria when
studying individual mycolic acid classes in these species. These
data are not very surprising, given the range of growth condi-
tions to which environmental species are exposed and must
adapt to, including possibly via modification of their mycolic
acid content. Although this adaptability is more pronounced in
environmental mycobacteria, pathogenic species also face dif-
ferent hostile conditions encountered in infectedmacrophages,
which require adaptation to maintain virulence (19, 20).
In this work we describe the involvement of a novel protein:
the epoxide hydrolase EphD from M. tuberculosis H37Rv and
its ortholog MSMEG_4280 from M. smegmatis mc2155, here-
after referred to as EphDtb and EphDsmeg, respectively, in the
metabolism of mycolic acids in mycobacteria.
Results
Epoxide hydrolases (EHs) are enzymes that catalyze the addi-
tion of water to epoxides to yield the corresponding 1,2-diols
and can use a broad range of substrates, among which are lipids
such as arachidonic acid and cholesterol metabolites (Fig. 1A)
(21). EphDtb is one of the seven putative EHs predicted in the
genome of M. tuberculosis H37Rv, six of which (EphA–EphF)
share similarity to mammalian EHs and one of which (EphG) is
related to the limonene EH fromRhodococcus erythropolis (22).
So far, none of these EHs was ascribed a physiological function,
although mycobacterial EHs have been suggested to play a role
in fatty acid metabolism (23). Contrary to all other human-like
soluble EHs, proteins EphD and EphE are conserved across the
Mycobacterium genus. Comparing bioinformatic data of EHs
fromM. tuberculosis, EphDtb shows several distinct features: (i)
it is the only membrane-associated putative EH and (ii) along
with having an /-hydrolase domain characteristic of most
soluble EHs, it contains a C-terminal short-chain dehydroge-
nase (SDR) domain (Fig. S2).
EphDtb and EphDsmeg are functional epoxide hydrolases
The epoxide hydrolase activity of EphDtb and EphDsmeg was
tested using cell-free extracts ofEscherichia coli strains produc-
ing these proteins, as well as recombinant proteins correspond-
ing to the individual EH and SDR domains of EphDtb. Testing
EH activity in cell-free extracts of E. coli without the need to
purify individual proteins is possible due to the lack of endoge-
nous EH activity in this microorganism (24). The ephD gene
from M. smegmatis mc2155, orthologous gene from M. tuber-
culosis H37Rv and the EH- and SDR-encoding segments of
ephDtb were individually expressed as C-terminal histidine-
tagged proteins in E. coli BL21(DE3) using the expression sys-
tem pET29a (Fig. 1B). Cell-free extracts from the resulting
strains BL21(DE3) pET29a-ephDtb, BL21(DE3) pET29a-
ephDtb-EH, BL21(DE3) pET29a-ephDtb-SDR, and BL21(DE3)
pET29a-ephDsmeg together with the control strain BL21(DE3)
pET29awere used as enzyme sources in anEHassaywhere each
recombinant protein was tested for its ability to hydrolyze the
generic substrate [14C]9,10-cis-epoxystearic acid (Fig. 1C) (25).
TLC analyses of organic solvent-extracted lipids clearly
demonstrated that cell-free extracts from the EphDtb- and
EphDsmeg-producing strains, but not those from the control
strain, were capable of converting 9,10-epoxystearic acid into
the corresponding diol. The identity of the diol product was
confirmed by LC-MS/MS (Fig. S3). Formation of the diol was
also evident when a cell-free extract from BL21(DE3) pET29a-
ephDtb-EH was used as an enzyme source, whereas the lipids
extracted from the reaction containing BL21(DE3) pET29a-
ephDtb-SDRwere comparable to the negative control (Fig. 1C).
We thus conclude that EphDtb and EphDsmeg are functional
EHs in vitro and that the /-hydrolase domain of EphD alone
is responsible for this activity. In the context of this study, we
addressed also the epoxide hydrolase activity of all remaining
putative EHs from M. tuberculosis H37Rv, and we confirmed
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that all of these proteins except EphC catalyze the cleavage of
9,10-epoxystearic acid (Fig. 1, B and D).
M. smegmatis overproducing EphD possesses altered lipid and
mycolic acid compositions
To assess the effect of ephD expression on lipids andmycolic
acids, EphDtb and EphDsmeg were individually overproduced in
M. smegmatis mc2155 using the inducible expression system
pHAM at three different temperatures. The production of
recombinant proteins was confirmed byWestern blotting anal-
ysis and immunodetection with anti-His antibodies (Fig. S4).
The cells were harvested, and the total lipids extracted from
these cells were analyzed by TLC in different solvent systems.
Comparedwith the negative control strain, strains overproduc-
ing EphDtb and EphDsmeg synthesized a novel lipid species (X)
migrating slightly faster than TMM (Fig. 2A). Moreover, anal-
ysis of mycolic acid methyl esters (MAMEs) extracted and fur-
ther derivatized from the same batch of whole cells revealed a
new fatty acid (Y) correlating with depletion of epoxymycolates
in the overproducing strains (Fig. 2B). Interestingly, these
changes were not observed in cells grown at 42 °C.
Next, we analyzed fatty andmycolic acid compositions of the
individual mycolic acid-containing molecules including TMM,
TDM, delipidated cell residues, and lipid X synthesized by the
overproducing strains grown at 30 °C. Individual lipids were
purified by preparative TLC and further subjected to saponifi-
cation, and free fatty andmycolic acidswere derivatized to their
corresponding methyl esters and analyzed by TLC. This
unveiled that the majority of species Y is bound to populations
of extractable lipids, mainly TMMand lipid X; surprisingly, the
latter compound contained practically no -, -, or epoxymy-
colates (Fig. 3). Y in the form of methyl ester was further iso-
lated using preparative TLC and subjected to structural analy-
sis. MALDI-TOF mass spectrometry showed that species Y
represents a series of odd and even carbon number mycolic
acids with mass values expected for dicarboxymycolates (m/z
925 (C57), 939 (C58), 953 (C59), 967 (C60), and 981 (C61)) (26).
The presence of an -carboxyl group in molecules of popula-
tion Y was confirmed by 1H NMR spectroscopy, with charac-
teristic singlets at 3.65 and 3.70 ppm, corresponding to the sig-
nals of two methyl protons linked to carboxyl groups (Fig. S5).
Figure 1. Epoxide hydrolase activity of EphA–EphG proteins in vitro. A, reaction catalyzed by EH. B, analysis of recombinant protein production in E. coli
BL21(DE3) pET29a, BL21(DE3) pET29a-ephDtb, BL21(DE3) pET29a-ephDtb-EH, BL21(DE3) pET29a-ephDtb-SDR, BL21(DE3) pET29a-ephDsmeg, BL21(DE3) pET29a-
ephAtb, BL21(AI) pDEST17-ephBtb, BL21(DE3) pET29a-ephCtb, BL21(AI) pET28a-ephEtb, and BL21(DE3) pET28a-ephFtb. (The line with recombinant EphG is not
shown because the signal was hardly visible.) SDS-PAGE analysis of 10,000 g supernatants of cell lysates, 60g of proteins were loaded per lane. Recombi-
nant proteins were detected by Western blotting analysis and immunodetection with anti-His antibodies. C, TLC analysis of the reaction products resulting
from the incubation of [14C]9,10-cis-epoxystearic acid with E. coli BL21(DE3) pET29a, BL21(DE3) pET29a-ephDtb, or BL21(DE3) pET29a-ephDsmeg fractions for
5–120 min at 37 °C and E. coli BL21(DE3) pET29a, BL21(DE3) pET29a-ephDtb-EH, BL21(DE3) pET29a-ephDtb-SDR, and BL21(DE3) pET29a-ephDtb for 60 min. The
plates were developed using n-hexane:diethyl ether:formic acid (70:30:2) and exposed to autoradiography film at80 °C for 2–5 days. D, TLC analysis of the
products of the EH assays containing 10,000 g supernatants of lysates of E. coli BL21(DE3) pET29a, BL21(DE3) pET29a-ephAtb, BL21(AI) pDEST17-ephBtb, BL21
(AI) pET28a-ephEtb, BL21(DE3) pET28a-ephFtb, and BL21(DE3) pET29a-ephGtb as the enzymatic sources. The reactions ran for 1 h at 37 °C. The plates were
developed and exposed as described above.
Metabolism of epoxymycolic acids inmycobacteria
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Similar dicarboxy mycolic acids were previously reported in
several Mycobacterium species that synthesize wax-ester
mycolates, such as Mycobacterium aurum, Mycobacterium
phlei, or theMycobacterium avium–intracellulare–scrofulaceum
complex (27–30). Dicarboxymycolates are formed from wax-
ester mycolates of these strains during the isolation of mycolic
acids from their native complex forms, which involves drastic
hydrolysis in alkaline conditions (saponification).
M. smegmatis overproducing EphD produces uniquemycolic
acids containing internal ester
To confirm whether detected dicarboxymycolates really
originated from wax-ester mycolates, we attempted circum-
venting the need for saponification.We reasoned that the pres-
ence of wax-ester mycolates should be detectable by MALDI-
TOF analysis of the purified intact lipid molecules TMM and
lipid X. The comparative analysis ofMALDI-TOFmass spectra
of TMM from control and overproducing strains yielded the
following results (Table 1): In the mass spectra of TMM from
the control strain, the peaks with [MNa] at m/z 1470 and
1498were assigned to TMMwith C77 andC79-mycolic acids
and the peaks of [MNa] at m/z 1514 and 1528 to the main
representatives of TMM with C79 and C80 epoxymycolic
acids. In the case of TMM from EphDtb- and EphDsmeg-over-
producing strains, themass valueswere respectively assigned to
TMM with -C77 and -C79, as well as epoxy-C79–C80 as in
the control strain, but also additional peaks atm/z 1502, 1516,
1530, and 1544 were observed. The mass values of these peaks
could be interpreted as TMMmolecules bearing a supplemen-
tary oxygens in the meromycolate chain (31).
Each representative peak was further analyzed by MS/MS
fragmentation, which confirmed the identity of trehalose esters
by the appearance of a fragment atm/z 715, indicating C2–C3
cleavage of the mycolate unit releasing a C24 fragment with
trehalose (Table S1). Loss of glucose in high mass values was
observed in all of the samples, as well as the presence of a peak
atm/z 365, assigned to trehalose.
Comparative 1H NMR studies of TMM isolated from the
control and EphD-overproducing strains confirmed the pres-
ence of disaccharide trehalose with one glucose acylated at the
6 position, as well as 2-alkyl 3-hydroxy fatty acids (H-2 andH-3
at 2.35 and 3.60 ppm). Other specific signals characteristic for
mycolic acids ofM. smegmatis were found, including those for
cis and trans double bonds and epoxy ring; this last signal was
absent in TMMs from both overproducers. The signals corre-
sponding to a wax-ester were not clearly identified. However,
MALDI-MS analysis of mycolic acids released after saponifica-
tion of TMM confirmed the presence of dicarboxymycolic
acids in the samples from the strains overproducing EphD
(Table 2). Interestingly, no diol mycolic acids were observed,
but the presence of peaks of pseudomolecular [MNa] spe-
cies at m/z 1220, 1234, 1248, and 1262 was identified in these
spectra. These mass values could be interpreted as either
hydroxy-mycolic acid (1220 for theC80 homolog) or long chain
Figure 2. Effect of EphD overproduction on lipids and mycolic acids in M. smegmatis. A, thin-layer chromatography of extracted lipids developed in
chloroform:methanol:water (20:4:0.5, v/v/v).CL, cardiolipin;PE, phosphatidylethanolamine;X, unknown lipid (see text fordetails).B, thin-layer chromatography
ofmycolic acidmethyl esters isolated fromwhole cells developed in n-hexane:ethyl acetate (95:5, v/v, three runs).,, and epoxy indicate individual types of
mycolic acid methyl esters. Y, unknown fatty acid (see text for details). pHAM lane, M. smegmatis mc2155 pHAM; ephDtb lane, M. smegmatis mc
2155 pHAM-
ephDtb; ephDsmeg lane,M. smegmatismc
2155 pHAM-ephDsmeg.
Figure 3. Mycolic acid composition of individual population of lipids
fromM. smegmatis overproducing EphD. Shown is thin-layer chromatog-
raphyofmycolic acidmethyl esters from isolatedpopulationsof TMMs, TDMs,
and lipid X and from delipidated cell pellets developed in n-hexane:ethyl
acetate (95:5, v/v, three runs). , , and epoxy indicate individual types of
mycolic acid methyl esters. pHAM lane, M. smegmatis mc2155 pHAM; ephDtb
lane, M. smegmatis mc2155 pHAM-ephDtb; ephDsmeg lane, M. smegmatis
mc2155 pHAM-ephDsmeg.
Metabolism of epoxymycolic acids inmycobacteria
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dicarboxylic mycolic acid (1248 for the C80 homolog) or
mycolic acid harboring an internal ester function; however, this
last structure needs strong alkaline conditions for their isola-
tion. These data together with the results ofMALDI-TOF anal-
ysis of the purified intact TMMs from EphD-overproducing
strains suggested that the analyzed TMM population contains
mycolic acids with internal ester group.
TheMALDI-TOFmass spectra of isolated intact lipid X con-
tained a mixture of three populations of lipids (Table S2): (i)
glycopeptidolipids represented by two peaks at m/z 1232 and
1260 corresponding to one series of the species-specific lipids
ofM. smegmatis and characterized by their fragmentation pat-
tern; (ii) trehalose -keto esters with C77 and C79 diethylenic
meromycolate chains, characterized by the main peaks with
[MNa] at m/z 1468 and 1496; These compounds, interme-
diates of mycolic acids synthesis, did not show C2–C3 cleavage
of the mycolate by MS/MS, as the hallmark of the mycolic acid
motif is absent in these molecules; and (iii) in the high mass
values, at m/z from 1740 to 1894, ultra long-chain complex
lipids ranging from C95 to C105 and belonging likely to the
TMMseries. TheMS/MS fragmentation of the long chain com-
pounds confirmed the nature of trehalose monomycolates by
the occurrence of peak at m/z 715 indicating C2–C3 cleavage.
Another peak resulting from this cleavage could be interpreted
as a possible fragment of the meroaldehyde at m/z 1068, 1173,
and 1201. The long-chainmycolic acid could explain the higher
migration of this TMMfraction. Ultra long-chainmycolic acids
possessing three functional groups have already been identified
as minor components of M. tuberculosis (32), and a recent
study has shown the involvement of the FASII hydroxyacyl
dehydratase HadBC in their synthesis (33).
MALDI-TOFmass spectrometry of fatty acids released after
saponification of lipid X and subsequently methylated showed
the appearance of peaks atm/z from 939 to 995 corresponding
to C58–C62 dicarboxymycolates, suggesting an internal ester
function in these molecules. Unfortunately, the small amounts
of the analyzed material did not allow carrying on their precise
characterization.
Table 1
Comparative MALDI-MS analysis of TMM
TMMwas isolated fromM. smegmatismc2155 pHAM (1),M. smegmatismc2155 pHAM-ephDtb (2), andM. smegmatismc2155 pHAM-ephDsmeg (3). The values represent
m/z of [MNa].
Type of mycolic acid
Number of carbons Unknown number
of carbons77 78 79 80 81 82
1. pHAM
- 1470 1498
Epoxy- 1486 1500 1514 1528 1542 1556
2. pHAM-ephDtb
- 1470 1498
Epoxy- 1486 1500 1514 1528
Unknown 1502
1516
1530
1544
3. pHAM-ephDsmeg
- 1470 1498
Epoxy- 1486 1500 1514 1528
Unknown 1502
1516
1530
1544
Table 2
Comparative MALDI-MS analysis of methylated mycolic acids
Methylatedmycolic acids were obtained by saponification andmethylation of TMM, isolated fromM. smegmatismc2155 pHAM (1),M. smegmatismc2155 pHAM-ephDtb
(2), andM. smegmatismc2155 pHAM-ephDsmeg (3). The values representm/z of [MNa].
Type of mycolic acid
Number of carbons Unknown number
of carbons58 59 60 61 77 78 79 80 81 82
1. pHAM
- 1174 1188 1202
Epoxy- 1190 1204 1218 1232 1246
2. pHAM-ephDtb 1174 1188 1202
- 1160 1188
Epoxy- 1176 1204 1218 1232 1246
Unknown 1220
1234
1248
1262
Dicarboxy- 939 953 967 981
3. pHAM-ephDsmeg
- 1160 1174 1188
Epoxy- 1176 1190 1204 1218 1232
Unknown 1220
1234
1248
1262
1276
Dicarboxy- 939 953 967 981
Metabolism of epoxymycolic acids inmycobacteria
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Saponification products of known wax-ester mycolates,
alongside dicarboxymycolates, are secondary alcohols 2-octa-
decanol and 2-eicosanol (29, 34, 35). To find these fragments,
the lipids extracted from the control and EphD-overproducing
strains were saponified, methylated, and analyzed by GC/MS
(data not shown). C16 and C18 fatty acid methyl esters
(FAMEs)were present in all of the strains and interestingly, also
-methyl branched FAMEs were characterized in EphD over-
producers on the basis of their retention time and the base peak
atm/z 88 characteristic for 2-methyl FAMEs, such as methyl-2
stearic acid and methyl 2-eicosanoic acid. In addition, minor
amounts of compounds such asmethyl ketone or small second-
ary alcohols (base peak m/z 57) were identified in the EphD
overproducers, but 2-octadecanol or 2-eicosanol were not
clearly detected.
Mycolic acids with internal ester are synthesized in parallel
with acetate uptake
The decreased amounts of epoxymycolic acids and the for-
mation of mycolates with internal ester inM. smegmatis over-
producing EphD raise the question of whether EphD catalyzes
the hydrolysis of the epoxy group on mature epoxymycolates
already esterified in lipids or whether it acts during their syn-
thesis. To distinguish between these hypotheses, we metaboli-
cally labeled M. smegmatis strains overproducing EphD with
[1,2-14C]acetate by adding the label either 8 h prior to the
induction of recombinant protein production or at the same
time as the inducer (acetamide) was added to the culture. The
cells were harvested after 3 or 24 h of further cultivation to
encompass different growth stages, and their mycolic acid
methyl esters obtained by saponification, extraction, andmeth-
ylation were analyzed by TLC (Fig. 4). Upon detection with
CuSO4, we observed the presence of dicarboxymycolates in
EphD-overproducing strains of both sets of samples (data not
shown). However, after autoradiography, the presence of
[14C]dicarboxymycolates was detected exclusively in the cells
in which [14C]acetate was added at the same time as EphD
production was induced. This suggests that EphD acts on
epoxymycolic acids during their synthesis.
EphD is involved in epoxymycolic acidmetabolism in slow
growingmycobacteria
We demonstrated the effect of EphD overproduction on the
metabolism of epoxymycolates inM. smegmatis, a fast-growing
Mycobacterium species in which this type of mycolic acids nat-
urally occurs. However, orthologs of EphD are found in slow-
and fast-growing Mycobacterium species alike, most of which
are not known to synthesize detectable amounts of epoxymy-
colates. In M. tuberculosis, the production of epoxymycolates
was observed under certain conditions. Upon disruption of the
gene encoding the mycolic acid methyltransferase Hma
(MmaA4), which is essential for the synthesis of methoxy- and
ketomycolates in both M. tuberculosis and M. bovis, an accu-
mulation of -mycolates was observed that accompanied the
build-up of small amounts of mycolates with a cis-epoxy group
at the distal position of themeromycolate chain (10).We used a
strain ofM. bovis BCGhma (36) to test, whether overproduc-
tion of EphD in this strain would affect its mycolic acid compo-
sition. Because acetamide-inducible expression systems are
usually unstable in slow-growing mycobacteria (37), we
attempted to constitutively express ephD using the pVV2 or
pVV16 expression plasmids, but without success.Wewere suc-
cessful, however, in generating strains of M. bovis BCG hma
producing the individual domains of EphD: EphDtb-EH and
EphDtb-SDR, using these plasmids. As expected, analysis of the
mycolic acids derived from the saponification and derivatiza-
tion of purified TMM, TDM, and delipidated cells from the
control strainM. bovisBCGhmapVV16 showed the presence
of -mycolates with minor amounts of epoxymycolates and
absence of ketomycolates (10) (Fig. 5). This profile was not
affected by the production of the SDRdomain of EphD. In sharp
contrast, the same lipids obtained from M. bovis BCG hma
producing the /-hydrolase domain of EphD were almost
completely devoid of epoxy species. TLC analysis of those sam-
ples did not reveal detectable amounts of dicarboxymycolates,
probably because of too-low amounts of epoxymycolates in
these samples or because of the absence of yet unknown
enzymes required for the synthesis of their precursors from
epoxymycolates. Nevertheless, based on these results, we sug-
gest that EphD is involved in themetabolismof epoxymycolates
also inM. bovis.
Disruption of ephD inM. tuberculosis impairs biosynthesis of
ketomycolic acids
By means of overproduction of EphD inM. smegmatis and
M. bovis BCG hma, we show that its activity leads to the
Figure 4. Metabolic labeling of M. smegmatis strains overproducing
EphD. The top panel shows a scheme of metabolic labeling of culture sets A,
B, C, and D described under “Experimental procedures”; also shown is an
autoradiogram of TLC analysis of radiolabeled fatty and mycolic acid methyl
esters fromwhole cells of cultures A and B (radioactive label added 8 h before
induction of recombinant EphD production) and C and D (label added in
parallel with induction of recombinant EphD production). The samples were
developed in n-hexane:ethyl acetate (95:5, v/v, three runs). , , and epoxy
indicate individual types of mycolic acid methyl esters; pHAM lane, M. smeg-
matis mc2155 pHAM; ephDtb lane, M. smegmatis mc
2155 pHAM-ephDtb;
ephDsmeg lane,M. smegmatismc
2155 pHAM-ephDsmeg.
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degradation/remodeling of epoxymycolates. To gain further
insight into the function of EphD, we disrupted the ephD
genes ofM. smegmatis andM. tuberculosis and analyzed the
effects of these knock-outs on mycolic acid metabolism in
both species.
M. smegmatismc2155 ephD was prepared by insertion of a
kanamycin cassette in the ORF of ephD gene in the region
encoding the/-hydrolase domain of the protein. Themutant
strain and the wildtype parent strain, M. smegmatis mc2155,
were cultivated in different media (Sauton, GAS, 7H9 ADC,
LB, and modified M63) at 20, 30, 37, or 42 °C, after which cells
were harvested and saponified, and their mycolic acids were
extracted,methylated, and analyzed byTLCas described above.
The growth of themutant strainwas significantly impaired, and
compared with the control, there was a significant clumping of
mutant cells in all of the tested conditions (Fig. S6). Neverthe-
less, no dramatic reproducible differences were found in the
fatty and mycolic acids profiles (data not shown). -Mycolates
in M. smegmatis were shown to comprise five subpopulations
(1–5) that differ one from another in their degree of cyclo-
propanation and methylation at the distal and proximal posi-
tions of the meromycolate chain (16, 17). Populations of -my-
colates from total mycolic acid extracts prepared from the
mutant and parent strains grown in modified M63 medium at
20, 30, or 42 °Cwere isolated by preparative TLC and individual
subpopulations further separated by argentation TLC. Again,
no reproducible differences between analyzed strains were
detected (data not shown).
Next, we constructed the mutant strain M. tuberculosis
H37RvephD harboring a hygromycin cassette insertion in the
/-hydrolase domain of ephD. Mycolic acids were isolated
from both the extractable lipids and delipidated cells of the
wildtype and mutant strains and analyzed by TLC. Disruption
of the ephD gene inM. tuberculosis H37Rv led to a decrease of
ketomycolates and an accumulation fatty/mycolic acid H (Fig.
6A). The accumulated species Hwas identified via comparative
LC-MS analysis of de-esterified samples of mycolic acidmethyl
esters prepared fromM. tuberculosisH37Rv andM. tuberculo-
sis H37Rv ephD as hydroxymycolic acids related to ketomy-
colates in the wildtype strain (Fig. 6B). Attempts to comple-
ment this phenotype by a functional copy of the ephDtb gene or
fragments of this gene encoding the individual domains of
EphD: EphDtb-EH and EphDtb-SDR, were not successful, prob-
ably because of the difficulty of constitutively overproducing
these proteins in M. tuberculosis H37Rv strain. However,
because the gene pepB (Rv2213) located in the downstream
vicinity of ephD is oriented in the opposite direction, we do
not expect that disruption of ephD affects downstream
genes. Based on these data, we concluded that the presence
of EphD is required for the synthesis of ketomycolic acids in
M. tuberculosis.
Discussion
As major lipid components of the mycomembrane, mycolic
acids are essential formycobacterial viability, which is reflected
in the fact that several important and effective antimycobacte-
rials such as isoniazid, ethionamide, isoxyl, and thiacetazone
target the FASII system (38, 39). Although non-essential per se,
oxygenated and cyclopropyl functionalities of the meromyco-
late chain in M. tuberculosis play significant roles in virulence
andmaintaining the integrity of the cell envelope (9, 11, 40, 41).
Reports of temperature-induced changes in the mycolic acid
composition of fast-growingmycobacteria such asM. smegma-
tis indicate that, much like changes in the fatty acid composi-
tion of phospholipids, modulation of the fine structure of
mycolic acidsmay contribute to the adaptation ofmycobacteria
to environmental conditions (15, 17, 18). In this work, we pro-
vided evidence of the involvement of a novel enzyme endowed
with epoxide hydrolase activity, present in both pathogenic and
environmental species of mycobacteria, in the metabolism of
mycolic acids. In vitro, EphD cleaves the epoxy group of the
generic substrate, 9,10-cis-epoxystearic acid. Defining the
physiological substrate of EphD, like that of any other mycolic
acid-modifying enzyme, is complicated by the complexity of
the biosynthesis of these very-long-chain fatty acids. To date, all
of the mycolic acid methyltransferases of M. tuberculosis have
been characterized solely on the basis of the phenotype of
recombinant knock-out or knock-in strains (2). We showed
that overproduction of the EphDenzyme fromM. smegmatis or
M. tuberculosis in M. smegmatis leads to a decrease in epoxy-
mycolates and an accumulation of mycolic acids with internal
ester, which are degraded to dicarboxylic mycolates by alkaline
treatment.
The origin of similar molecules, wax-ester mycolates, in myco-
bacteria has been shown to derive from the ketomycolic acids by
Baeyer–Villiger oxidation, i.e. insertion of molecular oxygen into
the hydrocarbon chain, thus converting a keto derivative into a
wax-ester (35) (Fig. 7A). Saponification of these mycolic waxes
releases the -carboxymycolic acids on one hand and the sec-
ondary alcohols, 2-octadecanol and 2-eicosanol, on the other.
Figure 5. Effect of overproduction of single domains of EphD inM. bovis
BCGhma. The results of thin-layer chromatography ofmycolic acidmethyl
esters from isolated populations of TMMs, TDMs, and from delipidated cell
pellets developed in n-hexane:ethyl acetate (95:5, v/v, three runs) are shown.
, epoxy, and keto indicate individual types of mycolic acid methyl esters.
Metabolism of epoxymycolic acids inmycobacteria
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However, the origin of dicarboxymycolic acids formed in
EphD-overproducing strains ofM. smegmatis can be explained
by another hypothetical pathway proposed on the basis of the
reaction sequence postulated for the degradation of limonene
in R. erythropolis (42). This reaction sequence includes the
opening of the oxirane ring providing a diol, followed by
oxidation of the diol, which transforms hydroxyl groups into
a ketone and the introduction of molecular oxygen between
these two functional groups by a Baeyer–Villiger monooxy-
genase (Fig. 7B).
Although the above-mentioned pathways are of a catabolic
process, metabolic labeling of M. smegmatis cells overproduc-
ing EphD show that 14C-labeled dicarboxymycolates, which are
probable degradation products of saponification of mycolates
containing internal ester, appear simultaneously with [14C]ac-
etate uptake, suggesting that the hydrolysis of the epoxy group
and subsequent reactions occur concurrently with the synthe-
sis of mycolates. We also found that the described modified
mycolic acids are present as trehalose esters. In addition, we
detected the-keto ester product ofmycolic condensation, and
Figure6. EffectofephDdisruptiononmycolic acids inM. tuberculosis.A, thin-layer chromatographyofmycolic acidmethyl esters isolated fromextractable
lipids and delipidated cells ofM. tuberculosis. H37Rv lane,M. tuberculosisH37Rv;ephD lane,M. tuberculosisH37RvephD. Chromatogramswere developed in
n-hexane:ethyl acetate (95:5, v/v, three runs). B, LC-MS comparative analysis of mycolic acids fromM. tuberculosis H37Rv andM. tuberculosis H37Rv ephD. ,
H, K, andM indicate -, hydroxy, keto-, and methoxymycolates.
Figure 7. Origin of dicarboxymycolic acids inmycobacteria. A, knownmetabolic pathway for wax-ester mycolates. B, pathway proposed in this work. The
mass values in blue are indicated for a C77 mycolyl-containing TMM. Functions between brackets in proximal position correspond to double bonds or
cyclopropane.
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in the highmass values we characterized a trehalosemonoester
with ultra long-chain mycolic acid. Characterization of
described intermediates as TMMderivativesmay suggest that a
certain regulatory point exists at the level of trehalose monoes-
ters. This notion is strengthened by the identification of tran-
sient acetylation of TMM required for periplasmic export of
this molecule in corynebacteria (43).
Our results further suggest that EphD is also involved in the
processing of epoxymycolates in slow-growingmycobacteria. It
is not clear why hma mutants of M. tuberculosis and M. bovis
BCG synthesize epoxymycolates because the substrate of this
methyltransferase has been proposed to contain a cis-double
bond (10, 36). It is possible that epoxidation serves as a starting
point for double bond degradation, although it cannot be
excluded that the complete loss of oxygenated mycolates is
unfavorable to these bacteria and that certain levels of epoxy-
mycolates are being synthesized by an unknown monooxyge-
nase to compensate for these changes and restore the integrity
of the mycomembrane.
Partial but specific loss of ketomycolates in aM. tuberculosis
H37Rv strain deficient in EphD that accompanied the accumu-
lation of their hydroxy precursors indicates impaired function
of the enzyme that oxidizes the hydroxylated products of Hma
to their keto-derivatives (44, 45). This begs the question of
whether EphD itself, or rather its SDR domain, could oxidize
hydroxy-mycolates to ketomycolates. Oxidation of hydroxy-
mycolates to ketomycolates was suggested to be catalyzed by
coenzyme F420-dependent dehydrogenase Rv0132c (46). Co-
production of this protein with methyltransferase Hma in
M. smegmatis stimulated production of keto-forms. We pre-
pared a strain of M. smegmatis co-producing both Hma and
EphDtb; however, the amount of ketomycolates in this strain
did not differ from the one producing Hma alone (not shown).
Indeed, the Hma producing M. smegmatis strain (also
described by Dubnau et al. (45)) synthesizes hydroxy- and
minor amounts of ketomycolates, probably as the result of
endogenous oxygenase activity inM. smegmatis. This indicates
that in mycobacteria there are at least two independent path-
ways for the production of keto-mycolic acids. To test whether
the observed production of ketomycolates is due to the activity
of the endogenous EphDsmeg, we produced the Hma protein in
M. smegmatis mc2155 ephD; however, we did not see any
changes in the production of ketomycolates in this strain com-
pared with the control (Fig. S7). Therefore, it is difficult to con-
clude whether EphD has a direct catalytic role in ketomycolate
synthesis inM. tuberculosis.
Under the conditions tested, we did not reveal any changes in
mycolic acids profile following the disruption of ephD in
M. smegmatis. Hence, we can hypothesize that in M. smegma-
tis, the activity of EphD is physiologically induced under condi-
tions that, for example, require changes in the amount of
epoxymycolates and those were not captured during our anal-
ysis. The regulatory mechanisms underlying the subtle struc-
tural changes in mycobacterial cell envelope lipids remain
essentially unknown (47). The activities of much of the FASII
enzymes seem to be regulated, at least by protein phosphoryla-
tion, as was demonstrated in several studies (48–52). In silico
analysis indicates a possible regulation of ephDtb by cyclic
AMP, which is often a signal for environmental or metabolic
changes in bacteria (53). Further efforts are needed to
explore the impact of this regulation and subsequent pheno-
typic changes on the adaptation of mycobacteria to environ-
mental changes.
Experimental procedures
Bacterial strains and growth conditions
E. coli strains XL1 andDH5were used for cloning purposes
and cultivated in LB (Luria–Bertani) medium (Invitrogen) at
37 °C with shaking. M. smegmatis mc2155 strains were grown
in modified M63 medium (7.6  102 M (NH4)2SO4, 0.5 M
KH2PO4, 1 mM MgSO4, 2% succinate, 0.025% tyloxapol, pH 7)
with shaking. M. tuberculosis and M. bovis BCG strains were
cultivated statically at 37 °C in Middlebrook 7H9 medium
(Difco) with the addition of 10% albumin-dextrose-catalase
(ADC) supplement and 0.05%Tween 80.When necessary, anti-
biotics were added into themedium: 20gml1 kanamycin; 20
gml1 hygromycin for mycobacteria or 100 gml1 hygro-
mycin for E. coli.
Gene cloning and expression
DNAs corresponding to ephAtb, ephCtb, ephDtb, ephDtb-EH,
ephDtb-SDR, ephDsmeg, ephEtb, ephFtb, and ephGtb were ampli-
fied from M. tuberculosis H37Rv or M. smegmatis mc2155
chromosomal DNA by PCR using primers listed in Table S3.
The resulting fragments corresponding to ephAtb, ephCtb,
ephDtb, ephDtb-EH, ephDtb-SDR, ephDsmeg, and ephGtb were
cloned into pET29a (Novagen) and fragments corresponding to
ephEtb and ephFtb were cloned into pET28a (Novagen) using
the NdeI and HindIII restriction sites. The protein EphB was
produced using pDEST17-ephD construct (54). Recombinant
strains of E. coli BL21(DE3) or E. coli BL21(AI) were grown in
LB medium at 37 °C to an A600 of 0.4–0.6, at which point the
production of recombinant proteins was induced with 0.4 mM
isopropyl--D-1-thiogalactopyranoside. The cells producing
EphD proteins were cultivated at 30 °C for an additional 4 h,
and the cells producing EphA, EphB, EphC, EphE, EphF, and
EphG proteins were cultivated at 16 °C for an additional 16 h.
The cells were harvested, washed with 50mMTris-HCl, pH 8.0,
and finally stored at20 °C.
Similarly, the ephDtb and ephDsmeg ORFs were PCR-ampli-
fied from M. tuberculosis H37Rv or M. smegmatis mc2155
chromosomal DNA (Table S3) and cloned into pHAM, a deriv-
ative of pJAM2 harboring a hygromycin resistance cassette (55)
using BamHI and XbaI for ephDtb or ScaI and XbaI for
ephDsmeg.M. smegmatismc2155 pHAM,M. smegmatismc2155
pHAM-ephDtb, and M. smegmatis mc2155 pHAM-ephDsmeg
were cultivated in modified M63 medium at 20, 30, or 42 °C
until A600 reached 0.6–0.9. At that point, recombinant protein
production was induced by adding 0.2% acetamide to the cul-
ture medium, and the cells were further grown at the given
temperatures for up to 72 h.
pVV16-ephDtb-EH was prepared by excision of the ephDtb-EH
fragment from pET29a-ephDtb-EH using NdeI andHindIII and
ligation into pVV16 cut with the same enzymes (56). The
ephDtb-SDR fragment was amplified from M. tuberculosis
H37Rv chromosomal DNA by PCR (Table S3) and cloned into
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the NdeI andHindIII restriction sites of pVV2 (57). Constructs
were introduced intoM. bovis BCG hma (obtained fromDr.
W. Jacobs (36)) by electroporation, and the resulting strains
were cultivated at 37 °C as described above. Production of
recombinant proteins was confirmed by SDS-PAGE and
immunodetection with anti-His antibodies.
Epoxide hydrolase assay
E. coli BL21(DE3) pET29a, BL21(DE3) pET29a-ephAtb,
BL21(AI) pDEST17-ephBtb, BL21(DE3) pET29a-ephCtb,
BL21(DE3) pET29a-ephDtb, BL21(DE3) pET29a-ephDtb-
EH, BL21(DE3) pET29a-ephDtb-SDR, BL21(DE3) pET29a-
ephDsmeg, BL21(AI) pET28a-ephEtb, BL21(DE3) pET28a-
ephFtb, and BL21(DE3) pET29a-ephGtb cells were suspended in
50 mM Tris-HCl, pH 8.0, and subjected to probe sonication in
the form of ten 20-s pulses with 40-s cooling intervals between
pulses. Sonicates were centrifuged for 10 min at 10,000  g,
and the resulting supernatants were kept frozen at 20 °C.
[14C]9,10-cis-Epoxystearic acid (56 mCi mmol1) was synthe-
sized from radiolabeled oleic acid as described by Müller et al.
(58), and the EH assay using this substrate was conducted as
described byArand et al. (25)withminormodifications. Briefly,
reaction mixtures containing 10,000 g supernatants of E. coli
extracts (100 g of proteins), [14C]9,10-cis-epoxystearic acid
(5,000 dpm), and 50 mM Tris-HCl buffer, pH 8.0, in a final
volumeof 250l were incubated from5 to 120min at 37 °C, and
the reactions were stopped by the addition of 500 l of ethyl
acetate. The samples were vortexed and centrifuged for 1 min
on a tabletop centrifuge. The upper organic phase was trans-
ferred to a clean tube and dried under a stream of nitrogen, and
half of thematerialwas analyzed byTLCusingn-hexane:diethyl
ether:formic acid (70:30:2) as the eluent. Radiolabeled com-
pounds were visualized by exposure of the developed silica
plates to Kodak BIOMAXMR film at80 °C.
Construction of deletion strains
The Ts-sacBmethod (59) was used to achieve allelic replace-
ment at the ephD loci of M. tuberculosis H37Rv and M. smeg-
matis mc2155. The M. tuberculosis ephD (Rv2214c) gene and
flanking regions was PCR-amplified from M. tuberculosis
H37Rv genomic DNA using primers KOF (5-actagtg-
gactcgggttgggc-3) and KOR (5-actagtaacaccgacgcggag-3)
and a disrupted allele, ephD::hyg, was obtained by insertion of
hygromycin resistance cassette into the KpnI restriction site of
ephD, thereby disrupting theN-terminal/ hydrolase domain
of the protein. ephD::hygwas then cloned into the SpeI-cut and
blunt-ended pPR27-xylE to obtain pPR27Rv2214cHX, the con-
struct used for allelic replacement inM. tuberculosis.
TheM. smegmatis ephD (MSMEG_4280; ephDsmeg) gene and
flanking regions were PCR-amplified from M. smegmatis
mc2155 genomic DNA using primers smg2214c.1 (5-cccga-
attcagcgggtcaccgtcccctctg-3) and smg2214c.2 (5-ggtctagacc-
acatgacgtccgacatgggtg-3), and a disrupted allele, ephDsmeg::
kan, was obtained by replacing 550 bp of the ephDsmeg
ORF flanked between two PmlI restriction sites with the
kanamycin resistance cassette from pUC4K (GE Healthcare).
ephDsmeg::kan was then cloned into the XbaI-cut and blunt-
ended pPR27-xylE to obtain pPR27ephDsmegKX, the construct
used for allelic replacement inM. smegmatis. The cells of con-
trol andmutant strains ofM. smegmatisused for lipid, fatty, and
mycolic acids analysis were cultivated in modified M63
medium for 4 and 9 days at 20 °C, for 24 h at 30 °C, and for 24 h
at 42 °C.
Lipid andmycolic acid analysis
Lipids were extracted from whole cells by 1.5 h of extraction
with chloroform:methanol (1:2) at 56 °C, followed by two 1.5-h
extractions with chloroform:methanol (2:1) at the same tem-
perature. Extracts were collected into a glass tube, dried under
a stream of nitrogen, and subjected to a wash in chloroform,
methanol, and water (4:2:1) (60). Dried organic phases of each
sample after this biphasic wash were dissolved in chloroform:
methanol (2:1) and analyzed by thin-layer chromatography on
silica gel 60 F254 plates (Merck) using chloroform:methanol:
water (20:4:0.5) as the eluent. Lipidswere visualized by spraying
the plates with 10% cupric sulfate in 8% phosphoric acid and
subsequent charring. Individual populations of selected lipids
were isolated by preparative TLC after visualization with 0.01%
rhodamine B. The silica corresponding tomigration of the ana-
lyzed population was scraped off the plate, and the lipids were
isolated by repeated extractions in the mixture of chloroform:
methanol (2:1).
Mycolic acids were isolated fromwhole cells, delipidated cell
pellets, or purified lipids (61). Briefly, 1 ml of 15% solution of
tetrabuthylammonium hydroxide was added to each sample,
and the samples were saponified at 100 °C overnight. After
cooling, 1.5 ml of dichloromethane, 1 ml of demineralized
water, and 150 l of iodomethane were added, and samples
were methylated for 4 h at room temperature on a rotary
shaker. Methylated samples were washed twice with water, and
the organic phase was transferred to clean tubes and dried
under nitrogen flow. Fatty and mycolic acid methyl esters
(FAMEs/MAMEs) were extracted with 2 ml of diethyl ether.
Dried samples were analyzed by TLC in n-hexane:ethyl acetate
(95:5, three runs) as the eluent and visualized as described
above. Different types of MAMEs were isolated by preparative
TLC as described above and analyzed on silver-impregnated
silica plates using dichloromethane as the eluent (16).
Metabolic labeling
Four sets (A, B, C, and D) of 10-ml cultures of modified M63
mediumwere inoculatedwith the cells ofM. smegmatismc2155
pHAM, M. smegmatis mc2155 pHAM-ephDtb, and M. smeg-
matis mc2155 pHAM-ephDsmeg to a final A600 of 0.01 and
cultivated at 30 °C with shaking. When A600 reached 0.07, 0.5
Ciml1 [1,2-14C]acetate (American Radiolabeled Chemicals;
specific activity, 106 mCimmol1) was added to the sets A and
B. The cultures were further cultivated until A600  0.3
when the production of recombinant proteins was induced
by adding 0.2% acetamide. Sets C and D were grown in par-
allel, and in their case [1,2-14C]acetate was added together
with acetamide at an A600 of 0.3. Aliquots of all of the
cultures were harvested after 3 h (sets A and C) or 24 h (sets
A and C) after induction.
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Structural analysis
MALDI-TOF/TOF-MS and MS/MS analyses were con-
ducted in the positive ionization and reflection mode by accu-
mulating 10 spectra of 250 laser shots, using the 5800 MALDI
TOF/TOF analyzer (Applied Biosystems/AB SCIEX) equipped
with aNd:YAG laser (349-nmwavelength). ForMS andMS/MS
data acquisitions, uniform, continuous, and random stage
motion was selected at a fixed laser intensity of 4000 (instru-
ment-specific units) and 400 Hz pulse rate and 6000 (instru-
ment-specific units) and 1000 Hz, respectively. For MS/MS
data acquisition, the fragmentation of selected precursor ions
was performed at collision energy of 1 kV. Lipid samples were
dissolved in chloroform and were directly spotted onto the tar-
get plate as 0.5-l droplets, followed by the addition of 0.5l of
matrix solution (2,5-dihydroxybenzoic acid, 10 mg/ml in
CHCl3/CH3OH, 1:1 (v/v)). Samples were allowed to crystallize
at room temperature. The spectra were externally calibrated
using lipid standards.
Gas chromatography-mass spectrometry
GC-MS of volatile fatty esters was performed with 1 l of
sample solubilized into petroleum ether, which was injected
into a Thermo Trace GC ultra chromatograph equipped with
an Inferno ZB5HT column of 15 m for fatty acid methyl ester
separation. The injector temperature was fixed at 220 °C with a
split ratio of 20:1. Helium was circulated at a constant flow rate
of 1.2 ml/min as a carrier gas. The oven temperature program
was as follows: initial temperature at 120 °C increased at 10 °C/
min to 380 °C (held for 3 min). The coupledmass spectrometer
ISQ was operated in electron impact ionization of 70 eV from
m/z 60 to 600, and the transfer line was maintained at 275 °C.
Nuclearmagnetic resonance
1H NMR spectra of purified lipids were obtained in CDCl3
(99.9% D) at 298 K using a 600-MHz Brucker Avance III spec-
trometer equippedwith a TCI cryoprobe. Chemical shift values
(in ppm) were relative to the internal CHCl3 resonance at 7.27
ppm.
LC-MS analysis of lipids andmycolic acids
LC-MS analysis of lipids and mycolic acids was as described
in Ref. 6.
LC-MS/MS analysis of cis-epoxystearic acid turnover
For the analysis of the products of the reaction by LC-MS/
MS, assays using non-radiolabeled cis-epoxystearic acid were
run. One microliter of 1 mM solution of cis-epoxystearic dis-
solved in acetonitrile was added to 100 l of E. coli crude
extracts (control and EphDtb producer). Mixtures were incu-
bated at 37 °C for 10 min and subsequently extracted with an
equal volume of ethyl acetate. After centrifugation for 3 min at
10,000  g, 50 l of the upper organic phase were transferred
into a new tube and evaporated under a gentle stream of nitro-
gen at 40 °C. The remaining material was dissolved in 100 l of
acetonitrile, sonified in a water bath for 3 min, and centrifuged
at 10,000 g. The supernatantwas analyzed on anAgilent 1100
liquid chromatography system using an Agilent eclipse XDB-
C18 reverse phase column (4.6  150 mm, 5-m pore size)
equipped with a corresponding Opti-Gard precolumn as the
stationary phase. The mobile phase consisted of (A) 0.1% for-
mic acid and (B) acetonitrile containing 0.1% formic acid at a
flow rate of 400 l/min. Samples were applied in an injection
volume of 20l. Starting conditions of 70% buffer Bweremain-
tained for 2 min, followed by a linear gradient from 70 to 100%
B within 8 min. An isocratic flow of 100% buffer B was held for
8 min. Thereafter, the column was re-equilibrated for 2 min
with 70% buffer B. The HPLC system was coupled to a 4000
QTRAP hybrid quadrupole linear ion trap mass spectrometer
(Applied Biosystems) equippedwith a TurboV source and elec-
trospray ionization interface. Analytes were recorded using
multiple reaction monitoring in the negative mode, using the
following source specific parameters: IS4500V, TEM 450 °C,
curtain gas (CUR  30 p.s.i.), nebulizer gas (GS1  50 p.s.i.),
heater gas (GS2 70 p.s.i.), and collision gas (CAD 10 p.s.i.).
9,10-dihydroxystearic acid was detected as a single homoge-
nous peak eluting at 8.2minusing the twomolecular transitions
m/z 315/297 (loss of water) and m/z 315/141 (-elimination)
for specific detection. These were previously established with
the molecular standard prepared by hydrolysis with recombi-
nant human soluble epoxide hydrolase (58).
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